These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20001555)

  • 21. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.
    Dinges S; Morard I; Heim M; Dufour JF; Müllhaupt B; Giostra E; Clavien PA; Mentha G; Negro F;
    Transpl Infect Dis; 2009 Feb; 11(1):33-9. PubMed ID: 19144096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
    Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of hepatitis C virus infection in patients with concurrent human immunodeficiency virus infection].
    Peters L; Lindhardt BØ
    Ugeskr Laeger; 2006 Oct; 168(42):3604-8. PubMed ID: 17069721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
    J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving anti-hepatitis C virus therapy.
    Pol S; Mallet VO
    Expert Opin Biol Ther; 2006 Sep; 6(9):923-33. PubMed ID: 16918259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study.
    Milazzo L; Caramma I; Mazzali C; Cesari M; Olivetti M; Galli M; Antinori S
    J Antimicrob Chemother; 2010 Apr; 65(4):735-40. PubMed ID: 20118492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
    Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
    Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
    Morishima C; Polyak SJ; Ray R; Doherty MC; Di Bisceglie AM; Malet PF; Bonkovsky HL; Sullivan DG; Gretch DR; Rothman AL; Koziel MJ; Lindsay KL;
    J Infect Dis; 2006 Apr; 193(7):931-40. PubMed ID: 16518754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis.
    Shire NJ; Welge JA; Sherman KE
    J Viral Hepat; 2007 Apr; 14(4):239-48. PubMed ID: 17381715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment duration for genotypes 2 and 3: still confusing after all these years.
    Jensen DM
    J Clin Gastroenterol; 2010 Sep; 44(8):527-8. PubMed ID: 20628314
    [No Abstract]   [Full Text] [Related]  

  • 32. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients.
    Maynard M; Pradat P; Gagnieu MC; Souvignet C; Trepo C
    Antivir Ther; 2008; 13(4):607-11. PubMed ID: 18672540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
    Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
    Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telaprevir.
    Drugs R D; 2010; 10(3):179-202. PubMed ID: 20945948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
    Trembling PM; Tanwar S; Dusheiko GM
    Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C: epidemiology, diagnosis, natural history and therapy.
    Pol S; Vallet-Pichard A; Corouge M; Mallet VO
    Contrib Nephrol; 2012; 176():1-9. PubMed ID: 22310776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New therapeutic strategies in HCV: second-generation protease inhibitors.
    Clark VC; Peter JA; Nelson DR
    Liver Int; 2013 Feb; 33 Suppl 1():80-4. PubMed ID: 23286850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Inhibitors of hepatitis C virus--current standards and status of investigations].
    Godzik P; Komorowski M; Cielecka-Kuszyk J; Madaliński K
    Przegl Epidemiol; 2010; 64(4):473-8. PubMed ID: 21473060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specifically targeted antiviral therapy for hepatitis C virus.
    Parfieniuk A; Jaroszewicz J; Flisiak R
    World J Gastroenterol; 2007 Nov; 13(43):5673-81. PubMed ID: 17963291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advance in antiviral drugs for hepatitis C.
    Liu J; Shi S; Zhuang H; Luo G
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Nov; 36(11):1025-36. PubMed ID: 22169716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.